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Abstract
Introduction: Guidelines dealing with severe sepsis and septic shock mostly rely on randomized controlled trials
(RCTs) to ensure the best standards of care for patients. However, patients included in high-quality studies may
differ from the routine population and alter external validity of recommendations. We aimed to determine to what
extent non-inclusion criteria of RCTs dealing with severe sepsis and septic shock may affect application of their
conclusions in routine care.
Methods: In a first step, the MEDLINE database was searched for RCTs treating severe sepsis and septic shock
patients between 1992 and 2008, and non-inclusion criteria for these studies were abstracted. Two reviewers
independently evaluated the articles, which were checked by a third reviewer. We extracted data on the study
design, main intervention, primary endpoint, criteria for inclusion, and criteria for non-inclusion. In a second step,
the distribution of the non-inclusion criteria was observed in a prospective multicenter cohort of severe sepsis and
septic shock patients (Cub-Rea network, 1992 to 2008).
Results: We identified 96 articles out of 7,012 citations that met the screening criteria. Congestive heart failure
(35%) and cancer (30%) were frequent exclusion criteria in selected studies, as well as other frequent disorders
such as gastrointestinal and liver diseases and all causes of immune suppression. Of the 67,717 patients with severe
sepsis and septic shock in the Cub-Rea database, 40,325 (60%) experienced at least one of the main exclusion
criteria, including 11% of congestive heart failure patients and 11% of cancer patients. In addition, we observed a
significant trend for increasing number of patients with these criteria along time.
Conclusion: Current exclusion criteria for RCTs dealing with severe sepsis and septic shock excluded most patients
encountered in daily practice and limit external validity of the results of high-quality studies.
Keywords: sepsis, septic shock, randomized controlled trial, exclusion criteria, co-morbidity, cohort
Introduction
Since the early 1990s, considerable efforts have been pro-
vided to improve treatment and global management of
patients suffering from severe infection. In August 1991,
the American College of Chest Physicians and the Society
of Critical Care Medicine released a landmark Consensus
Conference agreeing on definitions to be applied to
patients with severe infections [1]. Classifications were
provided to assist clinicians and researchers including
homogeneous and comparable populations in trials deal-
ing with severe sepsis and septic shock. Following this
conference, a number of major studies have been pub-
lished that substantially modified the management and
course of severe sepsis and septic shock patients. For the
same period, the mortality of patients with severe infec-
tions did not decrease [2] or remained high, suggesting
that physicians might be unaware of the scientific
advances in the field of severe infection.
Severe sepsis is a major problem in intensive care,
accounting for over 10 to 20% of stays of increased
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duration [3] and with a recent increase in hospitalization
[4]. The most severe presentation is septic shock with
an individual mortality that has recently slightly
decreased [5] but with an overall specific mortality that
has increased [6] due to the higher number of patients,
in particular older patients [7].
This observation prompted scientific societies to
develop a partnership that intended to provide standards
of care for management of severe sepsis and septic
shock, based on the highest levels of evidence published
scientific knowledge. Key recommendations overviewed
management of septic patients, including specific treat-
ments such as antimicrobial therapy, hemodynamic
management and use of adjunctive therapies, and sup-
portive care such as sedation, tight glucose control and
mechanical ventilation [8].
Implementation of these guidelines, however, has been
offset by a number of barriers. Heterogeneous levels of
equipment and resuscitation skills and overburden in
ICUs compromise the quality of care delivered to septic
patients, especially those requiring a high level of techni-
cal support [9,10]. Besides these organizational limita-
tions, the way these guidelines are applicable or not to
routine care patients is also controversial. One can sup-
pose that differences between groups of homogeneous
patients included in pivotal trials and real-life patients
routinely admitted to the ICU may prevent guideline
generalization. Even if non-inclusion criteria are known
to explain these differences, their identification and fre-
quency among routine ICU patients is lacking. As a con-
sequence, it is actually difficult to assess the proportion
of patients in whom the most current recommended
treatments were in fact not tested. To specifically address
whether international recommendations to treat septic
patients fit routine ICU patients or not, we first checked
for non-inclusion criteria in published randomized con-
trolled trials (RCTs) dealing with severe sepsis and septic
shock since 1992. In a second step, we investigated the
frequency of these non-inclusion criteria in a large ICU
population by using a multicenter ICU registry.
Patients and methods
First step: exclusion criteria in RCTs dealing with severe
sepsis and septic shock
We first identify the most frequent non-inclusion cri-
teria in RCTs dealing with severe infections.
Literature search strategy and inclusion criteria
The comprehensive literature searches included all trials
published in PubMed from 1 January 1992 to 31 Decem-
ber 2008. This period corresponded to that from release
of the first American College of Chest Physicians guide-
lines to the last update of bundles from the Surviving
Sepsis Campaign [3].
We included all trials (positive and negative) that
labeled the following MeSH keywords in the title and
abstract: sepsis; severe sepsis; septic shock; treatment;
randomized. We excluded trials in which no therapeutic
intervention was undertaken, and trials on ARDS since
sepsis is only one of the combining factors. Finally, we
selected interventional trials in populations with severe
sepsis and septic shock. All authors evaluated the eligibil-
ity of the trials, resolving disagreements by discussion
and consensus.
Data extraction
Two authors (HB, Y-EC) independently extracted data
that were checked by one author (AC). We noted the
study period, year of publication, and geographic area
where the study was performed. We detailed the study
design: monocenter or multicenter, randomized or not,
controlled or not, blind or open, financial disclosure (sup-
ported or not by the pharmaceutical industry or healthcare
societies). We checked whether Bone criteria [1] were
used or not to include patients, and whether mortality was
the main evaluation criteria. We described the number of
patients screened and excluded when available. Interven-
tions (treatment, strategy, procedure) were classified as fol-
low: vasopressors; fluid loading/global hemodynamic-
based strategy; steroids; antimicrobial agents; modulation
of immunity; coagulation-targeted therapy; miscellaneous.
We abstracted whether the results related to the primary
endpoint were positive or not.
For each trial, we carefully detailed the non-inclusion
criteria that we distributed between the following cate-
gories: pregnancy; age categories (<18 years, >75 years);
presence of congestive heart failure; presence of cancer
(excluding local skin cancer and cancer healed for at
least 6 months); gastrointestinal and liver disorder; HIV
infection; solid organ transplantation; treatment with
steroids; coagulation disorders or treatment; burns; renal
replacement therapy; overweight; neutropenia; cerebro-
vascular stroke; miscellaneous.
Second step: study cohort from the Cub-Rea database
This second step aimed to assess the distribution of
previously identified exclusion criteria in a large ICU
population.
Selection of patients from the database
The Collège des Utilisateurs de Bases de données en
Réanimation (Cub-Rea) database has been described else-
where [5,11,12]. In brief, the Cub-Rea network, created in
1992 by the Société de Réanimation de Langue Française
(Paris, France), is a record of admissions to 40 adult ICUs
in 35 hospitals located in and around Paris. According to
French regulations for ethical use of computerized data,
the Cub-Rea project was approved by the Comité National
Informatique et Liberté.
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Data were extracted from admissions to all the 40
ICUs participating in the database. We selected patients
included in the database from 1992 to 2008. As pub-
lished previously, the Cub-Rea group currently utilizes
the common definition for severe sepsis and septic
shock [1,5]. Data were extracted for ‘septicemia’, ‘sepsis’,
‘severe sepsis’ (defined as both an infection and an
organ failure) and ‘septic shock’, and for demographic
characteristics, dates of ICU admission and discharge,
category (medical, scheduled or unscheduled surgical)
and type of admission (community, hospital ward, or
institution), and immune status (immune deficiency
included HIV infection, ongoing malignancy, radiation
or chemotherapy, high dose or chronic use of corticos-
teroids, immune-suppressive drugs). Data were also
extracted for ‘site of infection’ and ‘type of microorgan-
isms’, and for ‘interventions’. The ICU length of stay
was calculated using the number of calendar days
between admission and discharge. Hospital mortality
rates were available from 1997 and readmission rates
during the same hospital stay were available from 1999
for all units.
Finally, we assessed the presence or absence of pre-
viously identified non-inclusion criteria among each of
these routine ICU patients.
Analyses
Unpaired t tests and c2 statistics were used for compari-
sons of continuous and nominal variables, respectively.
The changes from 1993 to 2008 for relevant variables
were analyzed by analysis of variance with the contrasts
method and by Pearson chi-squared analysis with the
Cochran-Armitage trend test for continuous and nom-
inal variables, respectively. P <0.05 was considered sig-
nificant in all multivariate analyses. Analyses were
performed with SAS statistical software (SAS Institute,
Cary, NC, USA).
Results
Exclusion criteria in RCTs dealing with severe sepsis
and septic shock
A search using ‘severe sepsis’, ‘septic shock’ and ‘treat-
ment’ as keywords in the PubMed database identified 7,012
publications from 1 January 1992 to 31 December 2008.
Among these publications, 734 were ‘randomized’ trials.
We selected 96 interventional trials including patients with
severe sepsis and septic shock after careful assessment of
each publication (Figure 1), corresponding to 26,875
included patients (see Additional file 1 for studies’ charac-
teristics and Additional file 2 for a complete publications’
list). The main intervention referred to vasopressors in 38
trials; fluid loading/global hemodynamic-based strategy in
eight trials; steroids in eight trials; modulation of immunity
in 29 trials; coagulation-targeted therapy in 11 trials; and
other adjunctive therapy in four trials. No study referred to
antimicrobial agents. Results did not support the primary
hypothesis in 63 studies. The number of patients screened
and patients excluded were reported in only 23 trials.
Among the 96 selected studies, 24 (corresponding to
2,163 patients) did not mention any exclusion criteria.
These trials were monocenter in 20 studies, and nine
studies were controlled and eight studies were double
blind. Results were positive for the primary endpoint in
33 studies. In these studies, the number of patients
screened and excluded was not reported. Mortality was
the primary endpoint in four studies.
The non-inclusion criteria used in the remaining 72
studies are reported in Table 1. Pregnant women were
excluded from 46 studies, patients aged <18 years from 39
studies, and patients aged >75 years from four studies.
The main underlying co-morbidities that led to patients’
exclusion were congestive heart failure (34 studies) and
cancer (30 studies). Gastrointestinal and liver disorders
were also frequent non-inclusion criteria. In 33 studies,
patients could not participate if they suffered from at least
one cause of severe immune suppression (combining
AIDS, neutropenia and transplant). Patients with coagula-
tion disorders or treatment interfering with hemostasis
could not be enrolled in 12 trials. Other miscellaneous
non-inclusion criteria appeared in 60 trials.
Study cohort from the Cub-Rea database
During the study period, 282,058 participants were
admitted in the ICUs participating in the Cub-Rea net-
work. Among these, 67,717 had severe sepsis and/or septic
shock (Figure 2). Among the whole ICU population, the
proportion of these patients with severe sepsis and/or sep-
tic shock progressively increased over time, and approxi-
mately doubled from 1992 (15.6%) to 2008 (30.9%,
P <0.0001). At least one non-inclusion criterion identified
in RCTs dedicated to severe infection was recorded in
40,325 (60%). Age >75 years was the most frequent non-
inclusion criterion (Table 2), accounting for 23% of the
population. Congestive heart failure and cancer were often
present. Disorders leading to severe immune suppression
were also frequently encountered. Of note, these exclusion
criteria were frequently combined (Table 2). Other condi-
tions leading to exclusion from RCTs were less frequent
and each had an impact below 10% of the studied popula-
tion. Interestingly, 14,009 (21%) patients had at least two
main non-inclusion criteria.
All along the study period, a time trend was observed
that corresponds to an increasing number of patients with
at least one non-inclusion criterion over years. A majority
of patients were free from non-inclusion criteria in 1992,
while 65.4% experienced at least one exclusion criterion in
2008. Patients >75 years of age represented <20% before
1997 and up to 27% in the late 2000s (Figure 3). This
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time-dependent change was observed for most non-inclu-
sion criteria. Among these criteria, overweight was subject
to the highest increase, as it was registered in <1% of
the population until 1996, and reached 5.7% in 2008
(P <0.0001). The number of pregnant women did not
change over time (P = 0.99). By contrast, AIDS (P <0.0001)
(see Additional file 3), cerebrovascular stroke (P <0.0001)
and burns (P = 0.02) significantly decreased during the
study period.
Finally, we compared patients with and without non-
inclusion criteria. Patients with at least one non-inclusion
criterion were older, had higher Simplified Acute Physio-
logical Score II, more frequently required vasopressors
and renal replacement therapy, and had worse outcome
(P <0.0001) (Table 3).
Discussion
In this article we demonstrate that RCTs dedicated to
treatment of severe sepsis and septic shock do not fit a
large part of the patients that are currently admitted to
ICUs with severe infection. Patients with common
co-morbidities, usual medications, cancer and various
immune deficiencies were not included in clinical trials
dealing with severe sepsis and septic shock although
such patients are likely to develop severe infections
[13]. Whether the results of these trials are applicable
to these frequently encountered ICU patients is
questionable.
RCTs are believed to currently provide the best level
of evidence that ensures efficacy of drugs interventions
or strategies. Regarding severe infections, their results
represent the basement of evidence-based clinical
knowledge and practices as recommendations of the
Surviving Sepsis Campaign [8]. Feasibility of such trials
requires homogeneous populations with selective char-
acteristics to allow group comparisons and internal vali-
dation. Characteristics of the population are therefore
tightly selected but lead to exclusion of potential partici-
pants. For instance, it has been reported that 23% trials
included in meta-analyses excluded no patients [14], and
Figure 1 Flow diagram of screened, eligible, and included
randomized controlled trials, and number of patients included.
Table 1 Exclusion criteria from randomized controlled trials dealing with severe sepsis and septic shock
Exclusion criteria Number (%) of
trials (n = 96)
Vasopressors
(n = 37)
Fluid
loading (n =
8)
Steroids
(n = 8)
Modulation of
immunity (n = 28)
Modulation of
coagulation (n = 11)
Miscellaneous
(n = 4)
Pregnancy 46 (47%) 16 (43%) 2 (25%) 4 (50%) 15 (54%) 6 (55%) 4 (100%)
Age <18 years 39 (40%) 7 (19%) 6 (75%) 5 (63%) 13 (46%) 7 (63%) 1 (25%)
Age >75 years 4 (4%) 1 (3%) 1 (13%) 1 (13%) 1 (4%) 0 0
Congestive heart
failure
34 (35%) 13 (35%) 2 (25%) 3 (38%) 12 (43%) 2 (18%) 1 (25%)
Cancer 29 (30%) 7 (19%) 2 (25%) 3 (38%) 11 (39%) 6 (55%) 2 (50%)
Gastrointestinal and
liver disorder
17 (18%) 6 (16%) 2 (25%) 2 (25%) 6 (21%) 3 (27%) 1 (25%)
Use of steroids 16 (16%) 0 0 7 (88%) 11 (39%) 0 0
HIV infection 15 (15%) 0 1 (13%) 3 (%) 9 (32%) 1 (9%) 0
Solid organ graft 14 (14%) 0 1 (13%) 4 (50%) 7 (25%) 2 (18%) 0
Coagulation
abnormalities
12 (12%) 0 1 (13%) 2 (25%) 5 (18%) 6 (55%) 0
Burns 11 (11%) 0 1 (13%) 3 (38%) 4 (14%) 3 (27%) 0
Renal replacement
therapy
11 (11%) 3 (8%) 1 (13%) 1 (13%) 3 (10%) 3 (27%) 0
Overweight 7 (7%) 0 0 0 2 (7%) 4 (36%) 0
Neutropenia 5 (5%) 1 (3%) 0 0 4 (14%) 0 0
Cerebrovascular
stroke
3 (3%) 0 1 (13%) 0 0 1 (9%) 0
Results expressed as number (%). Exclusion criteria were not mutually exclusive.
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the results were more significant in studies that
excluded patients. In the present study, the majority
(75%) of RCTs devoted to severe sepsis and septic shock
had non-inclusion criteria. Selecting patients is also
believed to decrease uncontrolled and unknown adverse
events in patients with severe underlying disorders. As a
consequence, more fragile patients cannot enter most
RCTs. Patients enrolled in clinical trials therefore some-
times differ from the actual target population. This may
result in a paradox where methodology oversights clini-
cal relevance. Research conducted by more than 300
analysts observed that older people were often excluded
from studies focused on Alzheimer’s dementia, arthritis
and incontinence [15]. RCTs may therefore lack external
validity. Consequently, efficacy and adverse outcome can
be ignored when translating scientific evidence into
daily practice.
Clinical practice addresses complex patients suffering
from multiple health problems that require multiple
medications. In a primary care population, patients eligi-
ble for five RCTs dealing with hypertension had 5 to 11
chronic conditions [16]. Ideally, RCTs would include
more complex and severe patients to allow translation of
results in daily practice. A recent review examined the
exclusion criteria in 283 RCTs published in high-quality
medical journals [17]. The subject of interest in these
Figure 2 Flow chart of patients from the Cub-Rea database (1992 to 2008). Cub-Rea, College des Utilisateurs de Bases de données en
Réanimation; RCT, randomized controlled trial.
Table 2 Exclusion criteria in patients from the Cub-Rea database with severe sepsis and septic shock.
Exclusion criteria At least one criterion One single criterion Combination of two criteria Combination of >2 criteria
40,325 26,316 10,599 3,410
Age <18 years 377 (0.6%) 217 (0.8%) 84 (0.8%) 76 (2.2%)
Age >75 years 15,871 (23%) 9,733 (37%) 4,854 (46%) 1,284 (38%)
Pregnancy 80 (0.1%) 43 (0.1%) 28 (0.3%) 9 (0.3%)
Congestive heart failure 7,457 (11%) 2,848 (11%) 3,364 (32%) 1,245 (37%)
Cancer 7,266 (11%) 2,810 (11%) 2,820 (27%) 1,636 (45%)
Severe immune suppressiona 8,930 (13%) 3,600 (14%) 2,975 (28%) 2,355 (69%)
AIDS 3,519 (5%) 2,400 (9%) 759 (7%) 360 (11%)
Neutropenia 2,949 (4%) 492 (2%) 1,270 (12%) 1,187 (35%)
Solid organ graft 2,462 (4%) 708 (3%) 946 (9%) 808 (24%)
Coagulation abnormalities 5,481 (8%) 1,567 (6%) 2,231 (22%) 1,613 (47%)
Gastrointestinal and liver disorders 5,416 (8%) 2,197 (8%) 2,003 (19%) 1,216 (36%)
Chronic renal failure requiring RTT 1,990 (3%) 660 (3%) 796 (8%) 534 (16%)
Overweight 2,027 (3%) 910 (3%) 716 (7%) 401 (12%)
Cerebrovascular stroke 1,953 (3%) 1,055 (4%) 639 (6%) 259 (8%)
Burns 160 (0.2%) 69 (0.2%) 55 (0.5%) 36 (0.1%)
Results expressed as number (%). CuB-Rea, College des Utilisateurs de Bases de données en Réanimation; RTT, renal replacement therapy. aSevere immune
suppression category combines patients with AIDS or neutropenia or transplant. Transplant category combines patients with bone marrow, kidney, liver, and
heart or lung transplant.
Claessens et al. Critical Care 2013, 17:R89
http://ccforum.com/content/17/3/R89
Page 5 of 9
articles was infectious diseases in 55 (19%) studies and cri-
tical care in eight (2.8%). Exclusion related to medication
and co-morbidities were frequent and poorly justified (for
details, see Additional file 4). As an example, cardiac disor-
ders are excluded from 24% of RCTs published in the
selected set of journals [17]. In western countries, conges-
tive heart failure is the most common underlying disorder
and the leading cause of death [12]. Additionally conges-
tive heart failure is a major co-morbidity associated with
death in septic patients. In our study, patients with con-
gestive heart failure were excluded in 34 (35%) articles
whereas the disorder was encountered in 11% patients
with severe infections from our database (Additional files
5 and 6).
Obviously disorders or treatments that deregulate innate
and adaptative immunity increase the risk for severe infec-
tions. Neutropenia, steroids, cancer and especially hemato-
logical malignancies are basically responsible for a burden
of infection. In a report of 283 trials including 35 RCTs
for treatment of oncologic and hematological malignan-
cies, cancer patients were excluded in 46 (16%) studies
and those with blood disorders in 59 (21%) [17]. Here we
Figure 3 Time trends of main exclusion criteria in septic patients from Cub-Rea database (1993 to 2008). Year 1992 was removed from the
graph because of nonrepresentative values related to the small sample. Cub-Rea, College des Utilisateurs de Bases de données en Réanimation.
Table 3 Characteristics and eligibility/non-eligibility distribution of severe sepsis and septic shock patients from
Cub-Rea
Total population (n = 67,717) Eligible for RCT (n = 27,392) Non-eligible for RCT (n = 40,325) P value
Age, years 64 (50 to 75) 58.2 (46 to 68) 69 (53 to 79) <0.0001
Gender, male 42,977 (63%) 18,177 (66%) 24,800 (62%) <0.0001
Charlson Index ≥2 8,366 (12%) 1,254 (5%) 7,112 (18%) <0.0001
Referred from ED 28,847 (42%) 12,730 (46%) 16,117 (40%) <0.0001
SAPS 2 46 (34 to 63) 38 (25 to 53) 49 (36 to 66) <0.0001
Mechanical ventilation 52,783 (78%) 21,290 (78%) 31,493 (78%) 0.249
Renal replacement therapy 12,654 (19%) 3,429 (13%) 9,225 (23%) <0.0001
Vasopressors 40,126 (59%) 14,211 (52%) 25,915 (64%) <0.0001
ICU mortality 22,970 (34%) 6,613 (24%) 16,357 (41%) <0.0001
In-hospital mortality 22,447 (33%) 6,088 (22%) 16,359 (41%) <0.0001
Characteristics of patients from the College des Utilisateurs de Bases de données en Réanimation (Cub-Rea) database with severe sepsis and septic shock, and
distribution according to their eligibility or non-eligibility to randomized controlled trials (RCTs). Results expressed as number (%) and median (interquartile
range). P <0.05 was statistically significant. ED, emergency department; SAPS, Simplified Acute Physiological Score.
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show that these were frequent exclusion criteria for
patients with severe infection, whereas they were fre-
quently encountered at the bedside. Besides these exclu-
sion criteria that can be forecast, other frequent
conditions might be underperceived as exclusion criteria
whereas they frequently impair the eligibility of septic
patients. This particularly applies to gastrointestinal and
liver disorders.
Pharmacological properties of medications are modi-
fied in physiological changes. Anticipating these varia-
tions is sometimes challenging. Obesity, an increasing
condition in western countries, is illustrative for this
paradigm. In obese patients, pharmacokinetics of drugs
may change as the volume distribution differs from non-
obese patients. We observed that overweight was a cri-
terion for exclusion in 7% trials while 18 to 32% of
American citizens present a body mass index >30 [18].
We observed in our population that obesity was a con-
dition that increased over time whereas it did not reach
the incidence recorded in North America. This may be
related to a different distribution of this condition in
our area [19] or to recent perception of the problem or
inadequate evaluation and underestimation of over-
weight. As obese patients may be at risk to develop
severe infections [20], and because their prognosis is
worsened [19], people with overweight should enter
RCTs dealing with severe sepsis and septic shock.
We observed that a minority of trials dealing with
severe infections excluded older patients. The burden of
infection encountered in western countries is related to
ageing. Additionally, age and mortality are closely
related in infectious diseases [21,22]. A number of
reports recently warned physicians on the exclusion of
older patients from RCTs [23,24]. More than 38% of
RCTs excluded patients over the age of 65 [17]. In trials
devoted to treatment of cancer, only 25% of patients
were older than 65 [25]. In our study, older patients
were excluded from only 4% of studies but the most
common cutoff was 75 years, which can be responsible
for an underestimating of age impact on non-inclusion.
The weight of co-morbidities on patients’ prognosis is
a usual concept in several fields of medicine. Their
impact has been extensively described in infectious dis-
orders [13,26,27]. In this setting, underlying disorders
are likely to impair prognosis by decreasing host defense
against the microorganism [28]. Alternatively, patients
are unable to face increasing oxygen demand because of
impaired physiological adaptation. In brief, co-morbid-
ities expose the patient to more severe infections [28].
Whereas excluding patients because of co-morbidities
allows recruitment of a homogeneous population in
RCTs, it may be detrimental for translation of evidence
into daily practice.
A major issue is to determine barriers to participate in
a clinical trial. Refusal occurs in one out of five patients
approached. Factors that influence the decision to
decline the invitation to enter a trial are poorly known
[29]. The most important reasons for failing entry into a
study remain lack of an adequate trial and unmet inclu-
sion criteria. This suggested a lack of pragmatic studies
addressing frequent clinical questions in patients with
common characteristics [30].
We identified several limitations in this study. First,
there might be some differences between non-inclusion
criteria extracted from RCTs and patients’ characteris-
tics. However, even if they exist, their relevance was lim-
ited and should have induced a negligible bias. Perhaps
more important, we were unable to identify both coagu-
lation disorders and use of steroids among the database
population. Consequently, no firm conclusion can be
drawn from our results regarding these two criteria.
Also we did not restrict our analysis to positive studies
but also to negative studies, since we considered that
these negative studies could have influenced the sepsis
guidelines in a similar manner. Finally, we tested only
one French database population, and a replication in a
different ICU population could have been useful.
Whereas we provide data from a large multicenter ser-
ies, patients we selected for severe sepsis and septic
shock may differ from other cohorts, even in western
countries. Indeed, assessment of these diagnoses may be
subjective, and the incidence of underlying disorders
may be not representative for other areas.
Conclusion
Here we demonstrate that RCTs dealing with severe
sepsis and septic shock infrequently include patients
with conditions that usually coexist and predispose to
severe infection in routine ICU patients. Moreover, we
also show that the frequency of these non-inclusion
conditions increased over recent years. Excluding
patients from analysis of intervention trials presumably
results in biased estimates of treatment effects, because
patients excluded may correspond to the actual target
population [14]. These findings advocate for extension
of entry criteria for participants with multiple co-mor-
bidities as they constitute the majority of patients with
severe sepsis and septic shock.
Key messages
• RCTs dealing with severe sepsis and septic shock
support current guidelines; however, these studies use
stringent exclusion criteria that lead to exclusion of
numerous patients.
• In an important cohort of patients with severe sepsis
and septic shock, 60% experienced at least one of the
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main exclusion criteria for RCTs dedicated to this
disorder.
• A significant trend for increasing number of patients
with these criteria is observed with time.
Additional material
Additional file 1: a table presenting the characteristics of selected
trials. *Categories that were not mutually exclusive.
Additional file 2: a complete list of publications selected for the
study.
Additional file 3: a figure showing the time trends of severe
immune suppression in septic patients from the Cub-Rea Database
(1993 to 2008). Severe immune suppression combined transplant,
neutropenia and AIDS. Year 1992 was removed from the graph because
of nonrepresentative values related to the small sample.
Additional file 4: a list presenting the classification of non-inclusion
criteria according to their justification [17].
Additional file 5: a table presenting the frequency of poorly
justified reasons among main non-inclusion criteria across studies’
categories [17]. Results are expressed as number of poorly justified
reason for non-inclusion/number of studies with each non-inclusion
criterion (%).
Additional file 6: a table presenting the non-inclusion criteria in
studies published in high impact factor journals.
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